Ardelyx shares climb as kidney-disease drug gets green light from Japanese regulators
Ardelyx Inc. shares (ARDX) gained 6% premarket on Monday after the company announced that its partner Kyowa Kirin Co. Ltd. received Japanese regulatory approval for tenapanor for patients with chronic kidney disease on dialysis. Tenapanor was approved for the improvement of hyperphosphatemia, a sign of kidney damage, in adults with the condition, Ardelyx said in a release. The approval triggers $30 million in milestone and licensing payments to Ardelyx from Kyowa Kirin as well as up to $10 million in additional payments from Healthcare Royalty Partners, Ardelyx said. The company is also seeking U.S. regulatory approval for tenapanor, with a decision expected by Oct. 17. Ardelyx shares have gained 38.6% in the year to date, while the S&P 500 has gained 12.5%.
-Eleanor Laise
This content was created by MarketWatch, which is operated by Dow Jones & Co. MarketWatch is published independently from Dow Jones Newswires and The Wall Street Journal.
(END) Dow Jones Newswires
09-25-23 0806ET
Copyright (c) 2023 Dow Jones & Company, Inc.-
Six Sports Betting and iGaming Stocks Trading at a Discount
-
4 Predictions for Stocks and the Economy for the Second Half of 2024
-
What Broadening Rally? AI Stocks Dominate Again In Q2
-
After Earnings, Is Nike Stock a Buy, a Sell, or Fairly Valued?
-
Worst-Performing Stock ETFs of the Quarter
-
Top-Performing Stock ETFs of the Quarter
-
Q2 In Review and Q3 2024 Market Outlook
-
5 Stocks to Buy for 3Q 2024
-
Industrials: Sector Offers Investment Opportunities as Performance Lags Broader Market
-
Consumer Defensives: Even Amid Macro Pressures, Deals Permeate the Landscape
-
33 Undervalued Stocks
-
Utilities: Can the Stocks Keep the Rally Going?
-
Basic Materials: Following Index Decline, We See Many Long-Term Opportunities
-
Healthcare: Valuations Look Attractive In Most Industries
-
Financial Services: Amid Uncertainties, We See the Most Value In Banks and Credit Services
-
Consumer Cyclicals: Even With Anxiety Over Spending, We See Attractive Valuations